NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

精密癌症診斷檢驗市場 - 預測,各地區、主要國家的市場分析,主要企業,COVID-19復甦方案:2021年∼2031年

Precision Cancer Diagnostic Test Market Report 2021-2031: Forecasts by Category, Cancer Imaging Test, Molecular Cancer Testing, End-user, Regional & Leading National Market Analysis, Leading Companies, and COVID-19 Recovery Scenarios

出版商 Visiongain Ltd 商品編碼 983574
出版日期 內容資訊 英文 449 Pages
商品交期: 最快1-2個工作天內
價格
精密癌症診斷檢驗市場 - 預測,各地區、主要國家的市場分析,主要企業,COVID-19復甦方案:2021年∼2031年 Precision Cancer Diagnostic Test Market Report 2021-2031: Forecasts by Category, Cancer Imaging Test, Molecular Cancer Testing, End-user, Regional & Leading National Market Analysis, Leading Companies, and COVID-19 Recovery Scenarios
出版日期: 2020年11月12日內容資訊: 英文 449 Pages
簡介

本報告提供全球精密癌症診斷檢驗市場相關調查分析,現狀,市場動態,市場預測,主要企業等相關的系統性資訊。

目錄

第1章 報告概要

第2章 摘要整理

第3章 癌症診斷概要

  • 診斷概要
  • LOAC技術
  • 多工傳統技術
  • 次世代定序技術
  • 聚合酵素鏈鎖反應 (PCR) 技術
  • 液態切片技術
  • 循環腫瘤細胞 (CTC) 技術
  • CTC工作流程
  • 細胞分離技術
  • CTC樣品製作技術
  • CTC下游分析技術
  • 癌症診察
  • 虛擬形象主導的診斷方法

第4章 推動市場要素、機會、課題

  • 全球推動市場要素
  • 世界的市場機會
  • 全球市場課題

第5章 全球精密癌症診斷檢驗市場預測

  • 市場分析:各金額 (COVID-19影響分析)
  • 各地區的市場分析 (COVID-19影響分析)
  • 全球市場分析:各類別 (COVID-19影響分析)
  • 全球市場分析:各癌症影像診斷檢驗類型 (COVID-19影響分析)
  • 全球市場分析:各分子癌症篩檢類型 (COVID-19影響分析)
  • 全球市場分析:各終端用戶 (COVID-19影響分析)

第6章 北美的精密癌症診斷檢驗市場預測

  • 市場分析:各金額 (COVID-19影響分析)
  • 市場分析:各國 (COVID-19影響分析)
  • 美國
  • 加拿大
  • 市場分析:各類別 (COVID-19影響分析)
  • 市場分析:各癌症影像診斷檢驗類型 (COVID-19影響分析)
  • 市場分析:各分子癌症篩檢類型 (COVID-19影響分析)
  • 市場分析:各終端用戶 (COVID-19影響分析)

第7章 歐洲的精密癌症診斷檢驗市場預測

第8章 亞太地區的精密癌症診斷檢驗市場預測

第9章 南美、中東、非洲的精密癌症診斷檢驗市場預測

第10章 下一代癌症診斷:主要舉措、計劃

  • Blood Profiling Atlas
  • CTC Trap Consortium
  • Human Cell Atlas
  • Next-Generation Single-Cell Analysis Program
  • Single-Cell Proteomics and Lipidomics Project
  • Worldwide Innovative Networking (WIN) Consortium

第11章 主要企業簡介

  • Abbott Laboratories Company
  • Agilent Technologies, Inc Company
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc. Company
  • Canon Medical Systems Corporation Company
  • Biocept, Inc Company
  • Roche Holding AG Company
  • Angle plc Company
  • Epigenomics AG Company
  • General Electric Company
  • Siemens AG Company
  • Biomerieux SA Company
  • Hologic, Inc Company
  • Myriad Genetics, Inc Company
  • 其他的主要企業

第12章 結論與建議

第13章 詞彙表

目錄
Product Code: PHA1015

Title:
Precision Cancer Diagnostic Test Market Report 2021-2031
Forecasts by Category (Cancer Imaging, Molecular Cancer Testing, Tumour Marker Immunoassays, POC Colon Cancer Tests), by Cancer Imaging Test (Computed Tomography, Magnetic Resonance Imaging, Digital & Analog Mammography, Positron Emission Tomography, Digital Breast Tomosynthesis, Molecular Breast Imaging), by Molecular Cancer Testing (Blood-Based Molecular Cancer Tests, HPV Genotyping, Circulating Tumour Cell (CTC) Tests, Next-Generation Sequencing Tests), by End-user (Hospitals, Clinics, Research Institutes) and Regional and Leading National Market Analysis PLUS Analysis of Leading Precision Cancer Diagnostic Test Companies AND COVID-19 Recovery Scenarios.

How this report can benefit CEOs and top management personnel to getting an edge in the global competition?

Overall industry success requires an effective balance of productivity in research and development, production efficiency, efficient marketing and distribution and customer service. Including new cancer cases, diagnostic procedures and product demand, across geographic markets, this report presents precision cancer testing indicators from 2021 until 2031 It is also explored in the segment's activities as a representative group of competitors working in the industry, involving selected companies.

Precision Cancer Diagnostics Test-our new study reveals trends, R&D progress, and predicted revenues

Where is the Precision Cancer Diagnostics Test market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 449 pages report provides 271 tables, 267 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Precision Cancer Diagnostics Test Market. See how to exploit the opportunities.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

Forecasts to 2031 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, there are following segments, each forecasted at a global and regional level.

How Precision Cancer Diagnostics Test Markets Will Perform in this COVID-19 Pandemic Situation?

In this pandemic situation, the Precision Cancer Diagnostics Test market has become more critical than ever in the last ten years. According to findings just released by the COVID-19 & Cancer Consortium, cancer patients with COVID-19 die three times the rate of non-cancer patients with the disorder. These new data are published in Cancer Discovery by CCC19 at a meeting of the American Association for Cancer Research, and are available to twice as many patients with COVID-19 and show that after 30 days there has been a boost in the mortality rate for cancer patients.

This report says TODAY how the development of cancer diagnostics test is driven by changes in the recession and booming COVID-19 in the next 10 years.

Find out the best-benefit areas for short- to long-term precision cancer diagnostic test and the future prospects. Our new study anticipates global domestic and regional sales. See the results, trends, chances and revenue projections. precision cancer diagnostic tests, there are many opportunities on the growing market. See how opportunities can be used today and how they can succeed.

Discover sales predictions for the world market and submarkets

Market Breakdown by Category (COVID-19 Impact Recovery Analysis Covered)

  • Cancer Imaging
  • Molecular Cancer Testing
  • Tumour Marker Immunoassays
  • POC Colon Cancer Tests

Market Breakdown by Cancer Imaging Test (COVID-19 Impact Recovery Analysis Covered)

  • Computed Tomography
  • Magnetic Resonance Imaging
  • Digital & Analog Mammography
  • Positron Emission Tomography
  • Digital Breast Tomosynthesis
  • Molecular Breast Imaging

Market Breakdown by Molecular Cancer Testing (COVID-19 Impact Recovery Analysis Covered)

  • Blood-Based Molecular Cancer Tests
  • HPV Genotyping
  • Circulating Tumour Cell (CTC) Tests
  • Next-Generation Sequencing Tests

Market Breakdown by End-User (COVID-19 Impact Recovery Analysis Covered)

  • Hospitals
  • Clinics
  • Research Institutes

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of Middle East & Africa

Leading companies and the potential for market growth

Overall world revenue for Precision Cancer Diagnostics Test Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Precision Cancer Diagnostics Test Market report helps you?

In summary, our 449-page report provides you with the following knowledge:

  • Revenue forecasts to 2031 for Precision Cancer Diagnostics Test Market, forecasted at a global and regional level- discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2031 for 5 regional and 14 key national markets - See forecasts for the Precision Cancer Diagnostics Test Markets market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Russia, China, India, and Japan, among other prominent economies.
  • Prospects for established firms and those seeking to enter the market- including company profiles for 15 of the major companies involved in the Precision Cancer Diagnostics Test Market.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company (BD)
  • Bio-Rad Laboratories, Inc.
  • Canon Inc.
  • Biocept, Inc.
  • Danaher Corporation (Danaher)
  • Roche Holding AG (Roche)
  • ANGLE plc
  • Epigenomics AG
  • General Electric Company
  • Siemens AG
  • Biomerieux SA
  • Hologic, Inc.
  • Myriad Genetics, Inc.

Buy our report today Precision Cancer Diagnostic Test Market Report 2021-2031: Forecasts by Category (Cancer Imaging, Molecular Cancer Testing, Tumour Marker Immunoassays, POC Colon Cancer Tests), by Cancer Imaging Test (Computed Tomography, Magnetic Resonance Imaging, Digital & Analog Mammography, Positron Emission Tomography, Digital Breast Tomosynthesis, Molecular Breast Imaging), by Molecular Cancer Testing (Blood-Based Molecular Cancer Tests, HPV Genotyping, Circulating Tumour Cell (CTC) Tests, Next-Generation Sequencing Tests), by End-user (Hospitals, Clinics, Research Institutes) and Regional and Leading National Market Analysis PLUS Analysis of Leading Precision Cancer Diagnostic Test Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1 Report Overview

  • 1.1 Scope of the Report
  • 1.2 Why You Should Buy This Report
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report Include:
  • 1.5 Who is This Report For?
  • 1.6 Methodology
    • 1.6.1 Primary Research
    • 1.6.2 Secondary Research
  • 1.7 Market Evaluation & Forecasting Methodology
  • 1.8 COIVD-19 Impact Recovery Pattern Analysis
    • 1.8.1 V-Shaped Recovery
    • 1.8.2 U-Shaped Recovery
    • 1.8.3 W-Shaped Recovery
    • 1.8.4 L-Shaped Recovery
  • 1.9 Frequently Asked Questions (FAQ)
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2 Executive Summary

3 Cancer Diagnostics Overview

  • 3.1 Diagnostics Overview
  • 3.2 Arrays and Microfluidics (LOAC) Technologies
    • 3.2.1 DNA Microarrays
    • 3.2.2 Protein Microarrays
    • 3.2.3 Microfluidics
  • 3.3 Multiplex Conventional Technologies
  • 3.4 Next Generation Sequencing Technology
  • 3.5 Polymerase Chain Reaction (PCR) Technology
  • 3.6 Liquid Biopsy Technologies
    • 3.6.1 Cancer Genomics
  • 3.7 Circulating Tumor Cell Technologies
  • 3.8 CTC Workflow
  • 3.9 Cell Isolation Technologies
    • 3.9.1 The main industry advocate of cell adhesion is Menarini-Silicon Biosystems
  • 3.10 CTC Sample Preparation Technologies
  • 3.11 CTC Downstream Analysis Technologies
    • 3.11.1 Comparison of Liquid Biopsy with Conventional Biopsy
  • 3.12 Cancer Testing
  • 3.13 Avatar-Driven Diagnostic Approaches

4 Market Drivers, Opportunities, and Challenges

  • 4.1 Global Market Drivers
    • 4.1.1 Increasing Global Spending On Oncology
    • 4.1.2 Are significant new product launches propelling the market growth?
    • 4.1.3 How Increased Cancer Patient Access and Value is Impacting Cancer Diagnostics Market?
  • 4.2 What are the Opportunities in the Global Market?
    • 4.2.1 How Modern Technologies will Drive growth for precision cancer diagnostic test market?
    • 4.2.2 Cancer Medicine Will Be Highly Personalized
    • 4.2.3 Innovations in Diagnostic Methods and Technology
  • 4.3 What Are the Challenges in the Global Market?
    • 4.3.1 Promising Diagnostic Tests Ultimately Fail Because Of Inadequate Performance In Real-World
    • 4.3.2 Rigorous Evaluation Of New Tests Has Been A Challenge
    • 4.3.3 Utilization Challenges for Precision Cancer Diagnostic tests
    • 4.3.4 The Cost Associated With Testing For Genomic Alterations And Subsequent Targeted Therapy, Poses Implementation Challenge

5 Global Precision Cancer Diagnostic Test Market Outlook

  • 5.1 Market Analysis by Value (COVID Impact Analysis)
    • 5.1.1 COVID-19 V-Shaped Recovery Analysis
    • 5.1.2 COVID-19 W-Shaped Recovery Analysis
    • 5.1.3 COVID-19 U-Shaped Recovery Analysis
    • 5.1.4 COVID-19 L-Shaped Recovery Analysis
    • 5.1.5 Global market is expected to grow at a CAGR of 9.8% during the forecast period 2021-2031
  • 5.2 Regional Market Analysis (COVID-19 Impact Analysis)
    • 5.2.1 COVID-19 V-Shaped Recovery Analysis
    • 5.2.2 COVID-19 W-Shaped Recovery Analysis
    • 5.2.3 COVID-19 U-Shaped Recovery Analysis
    • 5.2.4 COVID-19 L-Shaped Recovery Analysis
    • 5.2.5 North America is projected to Lead the Global Market During Forecast Period
  • 5.3 Global Market Analysis by Category (COVID-19 Impact Analysis)
    • 5.3.1 COVID-19 V-Shaped Recovery Analysis
    • 5.3.2 COVID-19 W-Shaped Recovery Analysis
    • 5.3.3 COVID-19 U-Shaped Recovery Analysis
    • 5.3.4 COVID-19 L-Shaped Recovery Analysis
    • 5.3.5 Cancer Imaging market is projected to grow at a CAGR of 9.7% and Lead the Market
  • 5.4 Global Market Analysis by Cancer Imaging Test Type (COVID-19 Impact Analysis)
    • 5.4.1 COVID-19 V-Shaped Recovery Analysis
    • 5.4.2 COVID-19 W-Shaped Recovery Analysis
    • 5.4.3 COVID-19 U-Shaped Recovery Analysis
    • 5.4.4 COVID-19 L-Shaped Recovery Analysis
    • 5.4.5 Magnetic Resonance Imaging Segment is Projected to Grow at the Fastest Rate
  • 5.5 Global Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
    • 5.5.1 COVID-19 V-Shaped Recovery Analysis
    • 5.5.2 COVID-19 W-Shaped Recovery Analysis
    • 5.5.3 COVID-19 U-Shaped Recovery Analysis
    • 5.5.4 COVID-19 L-Shaped Recovery Analysis
    • 5.5.5 HPV Genotyping Segment is Projected to be the Fastest Growing Segment in the Market
  • 5.6 Global Market Analysis by End-User (COVID-19 Impact Analysis)
    • 5.6.1 COVID-19 V-Shaped Recovery Analysis
    • 5.6.2 COVID-19 W-Shaped Recovery Analysis
    • 5.6.3 COVID-19 U-Shaped Recovery Analysis
    • 5.6.4 COVID-19 L-Shaped Recovery Analysis
    • 5.6.5 Hospitals Emerged as the Major User and is Projected to Maintain the Dominance

6 North America Precision Cancer Diagnostic Test Market Outlook

  • 6.1 North America Market Analysis by Value (COVID-19 Impact Analysis)
  • 6.2 North America Market Analysis by Country (COVID-19 Impact Analysis)
  • 6.3 US Market Analysis
    • 6.3.1 US Cancer Snapshot 2019
    • 6.3.2 US Market Analysis by Value (COVID-19 Impact Analysis)
    • 6.3.3 In 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States
  • 6.4 Canada Market Analysis
    • 6.4.1 Canada Cancer Snapshot 2019
    • 6.4.2 Canada Market Analysis by Value (COVID-19 Impact Analysis)
    • 6.4.3 It is estimated that in 2020, 115,800 Canadian men will be diagnosed with cancer
  • 6.5 North America Market Analysis by Category (COVID-19 Impact Analysis)
  • 6.6 North America Market Analysis by Cancer Imaging Test Type (COVID-19 Impact Analysis)
  • 6.7 North America Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
  • 6.8 North America Market Analysis by End-User (COVID-19 Impact Analysis)

7 Europe Precision Cancer Diagnostic Test Market Outlook

  • 7.1 Europe Market Analysis by Value (COVID-19 Impact Analysis)
  • 7.2 Europe Market Analysis by Country (COVID-19 Impact Analysis)
  • 7.3 Russia Market Analysis
    • 7.3.1 Russia Cancer Snapshot 2019
    • 7.3.2 Russia Market Analysis by Value (COVID-19 Impact Analysis)
    • 7.3.3. In Russia, the overall risk of dying from cancer is about 60%,
  • 7.4 Germany Market Analysis
    • 7.4.1 Germany Cancer Snapshot 2019
    • 7.4.2 Germany Market Analysis by Value (COVID-19 Impact Analysis)
    • 7.4.3 By 2030, prostate cancer will be the most common malignancy, surpassing breast cancer
  • 7.5 UK Market Analysis
    • 7.5.1 UK Cancer Snapshot 2019
    • 7.5.2 UK Market Analysis by Value (COVID-19 Impact Analysis)
    • 7.5.3 By 2035, the number of new cancer cases is projected to rise to over half a million a year
  • 7.6 France Market Analysis
    • 7.6.1 France Cancer Snapshot 2019
    • 7.6.2 France Market Analysis by Value (COVID-19 Impact Analysis)
    • 7.6.3 One in two men and one in three women will be diagnosed with cancer
  • 7.7 Italy Market Analysis
    • 7.7.1 Italy Cancer Snapshot 2019
    • 7.7.2 Italy Market Analysis by Value (COVID-19 Impact Analysis)
    • 7.7.3 In Italy, in 2018, over 369,000 new cases of cancer were diagnosed
  • 7.8 Rest of Europe Market Analysis by Value (COVID-19 Impact Analysis)
  • 7.9 Europe Market Analysis by Category (COVID-19 Impact Analysis)
  • 7.10 Europe Market Analysis by Cancer Imaging Test Type (COVID-19 Impact Analysis)
  • 7.11 Europe Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
  • 7.12 Europe Market Analysis by End-User (COVID-19 Impact Analysis)

8 Asia-Pacific Precision Cancer Diagnostic Test Market Outlook

  • 8.1 Asia-Pacific Market Analysis by Value (COVID-19 Impact Analysis)
  • 8.2 Asia-Pacific Market Analysis by Country (COVID-19 Impact Analysis)
  • 8.3 Japan Market Analysis
    • 8.3.1 Japan Cancer Snapshot 2019
    • 8.3.2 Japan Market Analysis by Value (COVID-19 Impact Analysis)
    • 8.3.3 Cancer is the leading cause of death in Japan for more than 30 years
  • 8.4 China Market Analysis
    • 8.4.1 China Cancer Snapshot 2019
    • 8.4.2 China Market Analysis by Value (COVID-19 Impact Analysis)
    • 8.4.3 China is undergoing the cancer transition stage where the cancer spectrum is changing from developing country to developed country
  • 8.5 India Market Analysis
    • 8.5.1 India Cancer Snapshot 2019
    • 8.5.2 India Market Analysis by Value (COVID-19 Impact Analysis)
    • 8.5.3 Cancer is emerging as a major public health concern in India
  • 8.6 Korea Market Analysis
    • 8.6.1 Korea Cancer Snapshot 2019
    • 8.6.2 Korea Market Analysis by Value (COVID-19 Impact Analysis)
    • 8.6.3 In 2018, over 240,000 patients were newly diagnosed with cancer in Korea
  • 8.7 Australia Market Analysis
    • 8.7.1 Australia Cancer Snapshot 2019
    • 8.7.2 Australia Market Analysis by Value (COVID-19 Impact Analysis)
    • 8.7.3 Around 30 years ago, about 5 in 10 people survived for at least 5 years after their cancer diagnosis
  • 8.8 Rest of Asia-Pacific Market Analysis by Value (COVID-19 Impact Analysis)
  • 8.9 Asia-Pacific Market Analysis by Category (COVID-19 Impact Analysis)
  • 8.10 Asia-Pacific Market Analysis by Cancer Imaging Testing Type (COVID-19 Impact Analysis)
  • 8.11 Asia-Pacific Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
  • 8.12 Asia-Pacific Market Analysis by End-User (COVID-19 Impact Analysis)

9 LAMEA Precision Cancer Diagnostic Test Market Outlook

  • 9.1 LAMEA Market Analysis by Value (COVID-19 Impact Analysis)
  • 9.2 LAMEA Market Analysis by Country (COVID-19 Impact Analysis)
  • 9.3 Brazil Market Analysis
    • 9.3.1 Brazil Cancer Snapshot 2019
    • 9.3.2 Brazil Market Analysis by Value (COVID-19 Impact Analysis)
    • 9.3.3 It is estimated that more than 600,000 new cases of cancer will be reported in Brazil
  • 9.4 Saudi Arabia Market Analysis
    • 9.4.1 Saudi Arabia Cancer Snapshot 2019
    • 9.4.2 Saudi Arabia Market Analysis by Value (COVID-19 Impact Analysis)
    • 9.4.3 The percentage of deaths due to cancer decreased after 70 years of age in Saudi Arabia population
  • 9.5 South Africa Market Analysis
    • 9.5.1 South Africa Cancer Snapshot 2019
    • 9.5.2 South Africa Market Analysis by Value (COVID-19 Impact Analysis)
    • 9.5.3 Lung cancer, cervical cancer, and oesophageal cancer are the three deadliest cancers in South Africa
  • 9.6 Mexico Market Analysis
    • 9.6.1 Mexico Cancer Snapshot 2019
    • 9.6.2 Mexico Market Analysis by Value (COVID-19 Impact Analysis)
    • 9.6.3 The main public health problems in the country are chronic degenerative diseases
  • 9.7 UAE Market Analysis
    • 9.7.1 UAE Cancer Snapshot 2019
    • 9.7.2 UAE Market Analysis by Value (COVID-19 Impact Analysis)
    • 9.7.3 The UAE is determined to bring down cancer fatalities by nearly 18 per cent by 2021
  • 9.8 Rest of LAMEA Market Analysis by Value (COVID-19 Impact Analysis)
  • 9.9 LAMEA Market Analysis by Category (COVID-19 Impact Analysis)
  • 9.10 LAMEA Market Analysis by Cancer Imaging (COVID-19 Impact Analysis)
  • 9.11 LAMEA Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
  • 9.12 LAMEA Market Analysis by End-User (COVID-19 Impact Analysis)

10 Next Generation Cancer Diagnostics: Key Initiatives and Programs

  • 10.1 Blood Profiling Atlas
    • 10.1.1 Cancer-ID
    • 10.1.2 Cancer Moon Shots
    • 10.1.3 China Precision Medicine Initiative
    • 10.1.4 ClinGen
  • 10.2 CTC Trap Consortium
    • 10.2.1 Early Cancer Detection Consortium
    • 10.2.2 EpiFemCare
    • 10.2.3 France Genomic Medicine Plan
    • 10.2.4 Friends of Cancer Research Project
  • 10.3 Human Cell Atlas
    • 10.3.1 Immunomonitor Consortium
    • 10.3.2 Integration of Imaging and Fluid-Based Tumour Monitoring
    • 10.3.3 Liquid Biopsies and Imaging for Improved Cancer Care
    • 10.3.4 Million Veteran Program
    • 10.3.5 MedSeq
  • 10.4 Next-Generation Single-Cell Analysis Program
    • 10.4.1 Population Sequencing Projects
    • 10.4.2 Precancer Atlas
    • 10.4.3 Precision Medicine Initiative
    • 10.4.4 Prompt
    • 10.4.5 QuIP Project
  • 10.5 Single-Cell Proteomics and Lipidomics Project
    • 10.5.1 TopMed
    • 10.5.2 Treehouse Childhood Cancer Initiative
    • 10.5.3 Very Rare Cancer Consortium
  • 10.6 Worldwide Innovative Networking (WIN) Consortium
    • 10.6.1 Single-Cell Research
    • 10.6.2 Cambridge Single-Cell Analysis Core Facility
    • 10.6.3 Harvard Medical School Single-Cell Core
    • 10.6.4 Mayo Medical Genome Facility
    • 10.6.5 National Center for Single-Cell Biology
    • 10.6.6 Single-Cell Analysis Core
    • 10.6.7 UC San Francisco Single-Cell Analysis Center
    • 10.6.8 Population Sequencing Programs

11 Leading Company Profiles

  • 11.1 Abbott Laboratories Company
    • 11.1.1 Company Information
    • 11.1.2 Company Overview
    • 11.1.3 Company Financial Profile
    • 11.1.4 Company Product Offerings
    • 11.1.5 Company Recent Developments
  • 11.2 Agilent Technologies, Inc Company
    • 11.2.1 Company Information
    • 11.2.2 Company Overview
    • 11.2.3 Company Financial Profile
    • 11.2.4 Company Product Offerings
    • 11.2.5 Company Recent Developments
  • 11.3 Becton, Dickinson and Company
    • 11.3.1 Company Information
    • 11.3.2 Company Overview
    • 11.3.3 Company Financial Profile
    • 11.3.4 Company Product Offerings
    • 11.3.5 Company Recent Developments
  • 11.4 Bio-Rad Laboratories, Inc. Company
    • 11.4.1 Company Information
    • 11.4.2 Company Overview
    • 11.4.3 Company Financial Profile
    • 11.4.4 Company Product Offerings
    • 11.4.5 Company Recent Developments
  • 11.5 Canon Medical Systems Corporation Company
    • 11.5.1 Company Information
    • 11.5.2 Company Overview
    • 11.5.3 Company Financial Profile
    • 11.5.4 Company Product Offerings
    • 11.5.5 Company Recent Developments
  • 11.6 Biocept, Inc Company
    • 11.6.1 Company Information
    • 11.6.2 Company Overview
    • 11.6.3 Company Financial Profile
    • 11.6.4 Company Product Offerings
    • 11.6.5 Company Recent Developments
  • 11.7 Danaher Corporation Company
    • 11.7.1 Company Information
    • 11.7.2 Company Overview
    • 11.7.3 Company Financial Profile
    • 11.7.4 Company Product Offerings
    • 11.7.5 Company Recent Developments
  • 11.8 Roche Holding AG Company
    • 11.8.1 Company Information
    • 11.8.2 Company Overview
    • 11.8.3 Company Financial Profile
    • 11.8.4 Company Product Offerings
    • 11.8.5 Company Recent Developments
  • 11.9 Angle plc Company
    • 11.9.1 Company Information
    • 11.9.2 Company Overview
    • 11.9.3 Company Financial Profile
    • 11.9.4 Company Product Offerings
    • 11.9.5 Company Recent Developments
  • 11.10 Epigenomics AG Company
    • 11.10.1 Company Information
    • 11.10.2 Company Overview
    • 11.10.3 Company Financial Profile
    • 11.10.4 Company Product Offerings
    • 11.10.5 Company Recent Developments
  • 11.11 General Electric Company Company
    • 11.11.1 Company Information
    • 11.11.2 Company Overview
    • 11.11.3 Company Financial Profile
    • 11.11.4 Company Product Offerings
    • 11.11.5 Company Recent Developments
  • 11.12 Siemens AG Company
    • 11.12.1 Company Information
    • 11.12.2 Company Overview
    • 11.12.3 Company Financial Profile
    • 11.12.4 Company Product Offerings
    • 11.12.5 Company Recent Developments
  • 11.13 Biomerieux SA Company
    • 11.13.1 Company Information
    • 11.13.2 Company Overview
    • 11.13.3 Company Financial Profile
    • 11.13.4 Company Product Offerings
    • 11.13.5 Company Recent Developments
  • 11.14 Hologic, Inc Company
    • 11.14.1 Company Information
    • 11.14.2 Company Overview
    • 11.14.3 Company Financial Profile
    • 11.14.4 Company Product Offerings
    • 11.14.5 Company Recent Developments
  • 11.15 Myriad Genetics, Inc Company
    • 11.15.1 Company Information
    • 11.15.2 Company Overview
    • 11.15.3 Company Financial Profile
    • 11.15.4 Company Product Offerings
    • 11.15.5 Company Recent Developments
  • 11.16 Other Leading Companies in the Market

12 Conclusion & Recommendations

  • 12.1 Recommendations for Clinicians
  • 12.2 Recommendations for Policy Makers

13 Glossary

List of Figure

  • Figure 5.1 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 5.2 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 5.3 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 5.4 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 5.5 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 6.1 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 6.2 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 6.3 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 6.4 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 6.5 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 6.6 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 6.7 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 6.8 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 6.9 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 6.10 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 6.11 US Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 6.12 Canada Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 6.13 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 6.14 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 6.15 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 6.16 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 6.17 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 6.18 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 6.19 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 6.20 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 6.21 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 6.22 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 6.23 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 6.24 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 6.25 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 6.26 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 6.27 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 6.28 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 6.29 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 6.30 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 6.31 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 6.32 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 7.1 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 7.2 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 7.3 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 7.4 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 7.5 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 7.6 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 7.7 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 7.8 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 7.9 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 7.10 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 7.11 Russia Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 7.12 Germany Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 7.13 UK Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 7.14 France Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 7.15 Italy Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 7.16 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 7.17 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 7.18 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 7.19 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 7.20 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 7.21 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 7.22 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 7.23 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 7.24 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 7.25 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 7.26 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 7.27 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 7.28 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 7.29 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 7.30 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 7.31 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 7.32 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 7.33 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 7.34 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 7.35 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 8.1 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 8.2 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 8.3 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 8.4 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 8.5 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 8.6 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 8.7 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 8.8 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 8.9 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 8.10 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 8.11 Japan Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 8.12 China Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 8.13 India Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 8.14 Korea Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 8.15 Australia Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 8.16 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 8.17 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 8.18 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 8.19 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 8.20 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 8.21 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 8.22 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 8.23 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 8.24 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 8.25 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 8.26 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 8.27 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 8.28 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 8.29 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 8.30 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 8.31 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 8.32 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 8.33 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 8.34 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 8.35 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 9.1 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 9.2 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 9.3 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 9.4 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 9.5 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 9.6 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 9.7 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 9.8 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 9.9 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 9.10 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 9.11 Brazil Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 9.12 Saudi Arabia Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 9.13 South Africa Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 9.14 Mexico Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 9.15 UAE Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
  • Figure 9.16 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 9.17 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 9.18 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 9.19 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 9.20 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 9.21 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 9.22 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 9.23 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 9.24 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 9.25 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 9.26 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 9.27 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 9.28 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 9.29 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 9.30 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 9.31 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
  • Figure 9.32 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
  • Figure 9.33 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
  • Figure 9.34 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
  • Figure 9.35 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
  • Figure 11.1 Abbott Laboratories Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.2 Abbott Laboratories Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.3 Abbott Laboratories Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.4 Abbott Laboratories Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.5 Agilent Technologies, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.6 Agilent Technologies, Inc: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.7 Agilent Technologies, Inc: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.8 Agilent Technologies, Inc: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.9 Becton, Dickinson and Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.10 Becton, Dickinson and Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.11 Becton, Dickinson and Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.12 Becton, Dickinson and Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.13 Bio-Rad Laboratories, Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.14 Bio-Rad Laboratories, Inc. Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.15 Bio-Rad Laboratories, Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.16 Bio-Rad Laboratories, Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.17 Canon Medical Sys Corp Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.18 Canon Medical Sys Corp. Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.19 Canon Medical Sys Corp. Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.20 Canon Medical Sys Corp. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.21 Biocept, Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.22 Biocept Inc. Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.23 Biocept Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.24 Biocept Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.25 Danaher Corporation Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.26 Danaher Corporation Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.27 Danaher Corporation Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.28 Danaher Corporation Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.29 Roche Holding AG. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.30 Roche Holding AG Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.31 Roche Holding AG. Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.32 Roche Holding AG. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.33 Angle plc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.34 Angle plc Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.35 Angle plc. Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.36 Angle plc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.37 Epigenomics AG. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.38 Epigenomics AG. Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.39 Epigenomics AG. Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.40 Epigenomics AG. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.41 General Electric Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.42 General Electric Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.43 General Electric Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.44 General Electric Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.45 Siemens AG Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.46 Siemens AG Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.47 Siemens AG Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.48 Siemens AG Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.49 Biomérieux SA Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.50 Kkk. Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.51 Biomérieux SA Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.52 Biomérieux SA Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.53 Hologic, Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.54 Hologic, Inc Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.55 Hologic, Inc Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.56 Hologic, Inc Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.57 Myriad Genetics, Inc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 11.58 Myriad Genetics, Inc Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.59 Myriad Genetics, Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.60 Myriad Genetics, Inc Company: Company Net Income/Loss 2015-2019 (US$ Mn)

List of Tables

  • Table 2.1 Global Precision Cancer Diagnostic Test Market Summary Table
  • Table 3.1 Diagnostic Market Segments
  • Table 3.2 Next Generation Diagnostics: Key Analysis Platforms
  • Table 3.3 Analysis Platforms and Biomarker Types
  • Table 3.4 DNA Microarray Technologies in Cancer Diagnostics
  • Table 3.5 Design Features of Protein Microarray Technologies
  • Table 3.6 Microfluidic LOAC Types Used in Cancer Diagnostics
  • Table 3.7 Advanced Sequencing Technologies
  • Table 3.8 Illumina Next Generation Sequencing Workflow
  • Table 3.9 Thermo Fisher Scientific's Next Generation Sequencing Workflow
  • Table 3.10 Main Ingredients of PCR Technology
  • Table 3.11 PCR Process
  • Table 3.12 Advantages of Droplet Digital PCR for Single-Cell Analysis
  • Table 3.13 Liquid Biopsy Biomarker Classes
  • Table 3.14 Cancer Genomic Sequencing and Liquid Biopsy
  • Table 3.15 Single-Cell Analysis to Identify Cancer Driver Mutations
  • Table 3.16 Genomics-Based Oncology Workflow
  • Table 3.17 Unique Challenges: CTC Capture and Analysis
  • Table 3.18 CTC Workflow
  • Table 3.19 Cell Differentiators
  • Table 3.20 Cell Isolation Technologies
  • Table 3.21 CTC Sample Preparation Technologies
  • Table 3.22 Single-Cell Analysis Technologies
  • Table 3.23 Estimated Annual Solid Biopsy Procedures, U.S., Selected Cancers
  • Table 3.24 Main Risks of Needle-Based Tissue Biopsies
  • Table 3.25 Factors in Tissue Biopsy
  • Table 3.26 Approaches to Avatar-Driven Cancer Diagnostics
  • Table 5.1 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 5.2 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 5.3 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 5.4 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 5.5 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 5.6 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 5.7 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 5.8 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 5.9 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 5.10 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 5.11 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 5.12 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 5.13 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 5.14 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 5.15 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 5.16 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 5.17 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 5.18 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 5.19 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 5.20 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 5.21 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 5.22 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 5.23 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 5.24 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 5.25 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 5.26 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 5.27 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 5.28 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 5.29 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 5.30 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 6.1 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 6.2 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 6.3 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 6.4 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 6.5 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 6.6 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 6.7 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 6.8 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 6.9 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 6.10 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 6.11 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 6.12 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 6.13 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 6.14 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 6.15 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 6.16 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 6.17 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 6.18 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 6.19 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 6.20 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 6.21 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 6.22 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 6.23 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 6.24 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 6.25 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 6.26 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 6.27 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 6.28 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 6.29 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 6.30 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 6.31 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 6.32 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 6.33 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 6.34 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 6.35 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 7.1 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 7.2 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 7.3 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 7.4 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 7.5 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 7.6 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 7.7 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 7.8 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 7.9 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 7.10 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 7.11 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 7.12 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 7.13 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 7.14 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 7.15 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 7.16 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 7.17 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 7.18 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 7.19 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 7.20 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 7.21 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 7.22 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 7.23 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 7.24 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 7.25 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 7.26 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 7.27 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 7.28 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 7.29 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 7.30 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 7.31 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 7.32 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 7.33 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 7.34 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 7.35 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 7.36 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 7.37 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 7.38 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 7.39 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 7.40 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 7.41 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 7.42 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 7.43 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 7.44 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 7.45 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 7.46 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 7.47 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 7.48 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 7.49 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 7.50 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 7.51 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 7.52 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 7.53 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 7.54 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 7.55 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 8.1 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 8.2 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 8.3 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 8.4 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 8.5 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 8.6 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 8.7 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 8.8 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 8.9 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 8.10 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 8.11 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 8.12 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 8.13 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 8.14 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 8.15 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 8.16 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 8.17 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 8.18 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 8.19 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 8.20 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 8.21 Korea Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 8.22 Korea Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 8.23 Korea Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 8.24 Korea Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 8.25 Korea Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 8.26 Australia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 8.27 Australia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 8.28 Australia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 8.29 Australia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 8.30 Australia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 8.31 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 8.32 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 8.33 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 8.34 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 8.35 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 8.36 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 8.37 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 8.38 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 8.39 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 8.40 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 8.41 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 8.42 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 8.43 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 8.44 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 8.45 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 8.46 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 8.47 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 8.48 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 8.49 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 8.50 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 8.51 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 8.52 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 8.53 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 8.54 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 8.55 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 9.1 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 9.2 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 9.3 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 9.4 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 9.5 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 9.6 Brazil Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 9.7 Brazil Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 9.8 Brazil Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 9.9 Brazil Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 9.10 Brazil Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 9.11 Saudi Arabia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 9.12 Saudi Arabia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 9.13 Saudi Arabia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 9.14 Saudi Arabia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 9.15 Saudi Arabia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 9.16 South Africa Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 9.17 South Africa Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 9.18 South Africa Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 9.19 South Africa Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 9.20 South Africa Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 9.21 Mexico Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 9.22 Mexico Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 9.23 Mexico Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 9.24 Mexico Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 9.25 Mexico Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 9.26 UAE Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 9.27 UAE Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 9.28 UAE Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 9.29 UAE Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 9.30 UAE Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 9.31 Rest of LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 9.32 Rest of LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 9.33 Rest of LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 9.34 Rest of LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 9.35 Rest of LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 9.36 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 9.37 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 9.38 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 9.39 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 9.40 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 9.41 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 9.42 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 9.43 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 9.44 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 9.45 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 9.46 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 9.47 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 9.48 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 9.49 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 9.50 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 9.51 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
  • Table 9.52 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
  • Table 9.53 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
  • Table 9.54 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
  • Table 9.55 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
  • Table 10.1 R &D: Next Generation Cancer Diagnostics
  • Table 10.2 Single-Cell Core Research Facilities
  • Table 10.3 Population Sequencing Projects
  • Table 11.1 Abbott Laboratories: Company Information
  • Table 11.2 Abbott Laboratories Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.3 Abbott Laboratories: Company Product and Service Offerings
  • Table 11.4 Abbott Laboratories: Company Recent Developments till Oct,2020
  • Table 11.5 Agilent Technologies, Inc: Company Information
  • Table 11.6 Agilent Technologies, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.7 Agilent Technologies, Inc: Company Product and Service Offerings
  • Table 11.8 Agilent Technologies, Inc: Company Recent Developments till Oct,2020
  • Table 11.9 Becton, Dickinson and Company: Company Information
  • Table 11.10 Becton, Dickinson and Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.11 Becton, Dickinson and Company: Company Product and Service Offerings
  • Table 11.12 Becton, Dickinson and Company: Company Recent Developments till Oct,2020
  • Table 11.13 Bio-Rad Laboratories, Inc: Company Information
  • Table 11.14 Bio-Rad Laboratories, Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.15 Bio-Rad Laboratories, Inc: Company Product and Service Offerings
  • Table 11.16 Bio-Rad Laboratories, Inc: Company Recent Developments till Oct,2020
  • Table 11.17 Canon Medical Sys Corp: Company Information
  • Table 11.18 Canon Medical Sys Corp Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.19 Canon Medical Sys Corp: Company Product and Service Offerings
  • Table 11.20 Canon Medical Sys Corp: Company Recent Developments till Oct,2020
  • Table 11.21 Biocept, Inc: Company Information
  • Table 11.22 Biocept Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.23 Biocept Inc: Company Product and Service Offerings
  • Table 11.24 Biocept Inc: Company Recent Developments till Oct,2020
  • Table 11.25 Danaher Corporation: Company Information
  • Table 11.26 Danaher Corporation Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.27 Danaher Corporation: Company Product and Service Offerings
  • Table 11.28 Danaher Corporation: Company Recent Developments till Oct,2020
  • Table 11.29 Roche Holding AG: Company Information
  • Table 11.30 Roche Holding AG. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.31 Roche Holding AG: Company Product and Service Offerings
  • Table 11.32 Roche Holding AG: Company Recent Developments till Oct,2020
  • Table 11.33 Angle plc: Company Information
  • Table 11.34 Angle plc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.35 Angle plc: Company Product and Service Offerings
  • Table 11.36 Angle plc: Company Recent Developments till Oct,2020
  • Table 11.37 Epigenomics AG: Company Information
  • Table 11.38 Kkk Epigenomics AG. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.39 Epigenomics AG: Company Product and Service Offerings
  • Table 11.40 Epigenomics AG: Company Recent Developments till Oct,2020
  • Table 11.41 General Electric Company: Company Information
  • Table 11.43 General Electric Company: Company Product and Service Offerings
  • Table 11.44 General Electric Company: Company Recent Developments till Oct,2020
  • Table 11.45 Siemens AG: Company Information
  • Table 11.46 Siemens AG Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.47 Siemens AG: Company Product and Service Offerings
  • Table 11.48 Siemens AG: Company Recent Developments till Oct,2020
  • Table 11.49 Biomérieux SA: Company Information
  • Table 11.50 Biomérieux SA Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.51 Biomérieux SA: Company Product and Service Offerings
  • Table 11.52 Biomérieux SA: Company Recent Developments till Oct,2020
  • Table 11.53 Hologic, Inc: Company Information
  • Table 11.54 Hologic, Inc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.55 Hologic, Inc: Company Product and Service Offerings
  • Table 11.56 Hologic, Inc: Company Recent Developments till Oct,2020
  • Table 11.57 Myriad Genetics, Inc: Company Information
  • Table 11.58 Myriad Genetics, Inc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Table 11.59 Myriad Genetics, Inc: Company Product and Service Offerings
  • Table 11.60 Myriad Genetics, Inc: Company Recent Developments till Oct,2020
  • Table 11.61 List of Other Leading Companies in the Global Market

List of Companies Profiled:

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ANGLE plc
  • Becton, Dickinson and Company (BD)
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biomerieux SA
  • Canon Inc.
  • Danaher Corporation (Danaher)
  • Epigenomics AG
  • General Electric Company
  • Hologic, Inc.
  • Myriad Genetics, Inc.
  • Roche Holding AG (Roche)
  • Siemens AG

List of Other Companies Mentioned in the Report:

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Angle plc
  • Apellis Pharmaceuticals
  • Baxter InternationalHealth care company
  • Becton Dickinson and Company
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • Biocartis N.V.
  • Biocept, Inc.
  • bioMérieux SA
  • Biotechnology company
  • Boston Scientific
  • Canon Medical Systems Corporation
  • Cardinal Health
  • Celyad Oncology
  • Cynvenio Biosystems, Inc.
  • Danaher Corporation
  • DePuy Synthes Companies
  • Edwards Lifesciences
  • Epigenomics AG
  • Exact Sciences Corporation
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc.
  • Freenome, Inc.
  • Galápagos NV
  • General Electric Company
  • GENEWIZ, Inc.
  • Genomic Health, Inc.
  • Globus Medical Inc
  • Hologic, Inc.
  • Illumina, Inc.
  • Medtronic Medical device company
  • Menarini Silicon Biosystems SpA
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • Nobel Biocare
  • Ortho Clinical Diagnostics
  • Orthofix
  • Pacific Biosciences
  • QIAGEN N.V.
  • Randox Laboratories Ltd.
  • Roche Holding AG
  • Royal Philips N.V.
  • Sartorius Stedim Biotech
  • Siemens AG
  • Smith & Nephew
  • Stryker Corporation
  • Thermo Fisher Scientific
  • Vela Diagnostics
  • Zimmer Biomet
  • Zymergen, Inc.

List of Organizations Mentioned in the Report:

  • Acoustic Neuroma Association
  • Acoustic Neuroma Association of Australia
  • Acoustic Neuroma Association of Canada
  • American Association for Cancer Research
  • American Bone Marrow Donor Registry
  • American Brain Tumor Association
  • American Cancer Society
  • American Cancer Society (ACS)
  • American Childhood Cancer Organization
  • American College of Radiation Oncology
  • American Gastroenterological Association
  • American Head and Neck Society
  • American Society for Radiation Oncology
  • American Society of Clinical Oncology
  • American Society of Pediatric Hematology/Oncology
  • Aplastic Anemia and MDS International Foundation
  • Armenian Association of Hematology and Oncology
  • Asian Society for Neuro-Oncology
  • Associação Brasiliense de Apoio ao Paciente com Câncer
  • Association for International Cancer Research
  • Association for Multiple Endocrine Neoplasia Disorders
  • Association for the Study of Lung Cancer
  • Association Francaise de La maladie de Fanconi
  • Association of Cancer Online Resources
  • Association of Cancer Physicians
  • Association of Community Cancer Centers
  • Association of European Cancer Leagues
  • Association of Gynecologic Oncologists of India
  • Association of Oncology Social Work
  • Association of Parents of Children with Cancer
  • Association of Pediatric Hematology / Oncology Nurses
  • Association of Population-based Cancer Registries in Germany
  • Association of Radiation Oncologists of India
  • Australasian Association of Cancer Registries
  • Australasian Lung Cancer Trials Group
  • Australian and New Zealand Children's Haematology/Oncology Group
  • Australian Association of Smoking Cessation Professionals
  • Australian Capital Territory Cancer Registry
  • Australian Cervical Cancer Foundation
  • Australian Familial Pancreatic Cancer Cohort
  • Australian Mesothelioma Registry
  • Australian Oncology Social Work Inc.
  • Australian Prostate Cancer Research
  • Australian Society of Gynaecologic Oncologists
  • Australian Thyroid Foundation
  • Austrian Cancer Society
  • Avon Breast Cancer Crusade
  • Bangladesh Cancer Society
  • BANO overview (UICC)
  • Barbados Cancer Society
  • BASO ~ The Association for Cancer Surgery
  • Bill & Melinda Gates Foundation
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Cancer Research UK
  • Defense Advanced Research Projects Agency
  • Friedrich-Loeffler-Institute
  • Institute of Immunology of the Centre de Recherche Public-Santé (CRP)
  • Karolinska Institutet
  • University of Pennsylvania (Penn)
  • World Health Organization (WHO)